Nov 20, 2012 by Brenton Flynn and Max MacalusoWhat's Changed With MAKO Surgical?MAKO Surgical talks about some uncertainties in the wake of Hurricane Sandy.
Nov 20, 2012 by Brenton Flynn and Max MacalusoWhat's Changed With Dendreon?A close look at the books at Dendreon.
Nov 20, 2012 by Brenton Flynn and Max MacalusoWhat's Changed With Questcor?Questcor makes a push for a new indication.
Nov 20, 2012 by Brenton Flynn and Max MacalusoWhat's Changed With Abbott Labs?Can a coming spinoff help increase margins?
Nov 19, 2012 by Brenton FlynnThis PBM's Loss Is UnitedHealth's GainExpress Scripts is losing a big customer in UnitedHealth.
Nov 19, 2012 by Brenton FlynnA Titan Goes After Intuitive SurgicalWill da Vinci be dethroned by Mozart?
Nov 19, 2012 by Brenton FlynnUnitedHealth's $300 Million MoveUnitedHealth looks to save costs by insourcing.
Nov 17, 2012 by Brenton Flynn3 Trends Driving Express Scripts ForwardThings might not be as bad as feared.
Nov 16, 2012 by Brenton FlynnThese MAKO Insiders Are Buying, Should You?There's only one reason to buy a stock.
Nov 16, 2012 by Brenton FlynnWill This Spinoff's Drug Save Shareholders?Will hepatitis C be the key to Abbvie's future?
Nov 16, 2012 by Brenton FlynnDynavax Shares Pummelled After FDA PanelThe outlook for Heplisav doesn't look too rosy.
Nov 14, 2012 by Brenton FlynnWhy This Medical Robot Is Best of BreedAre all medical robots created equal? No.
Nov 14, 2012 by Brenton FlynnHow Should You React to This MAKO News?It's raising $40 million in capital by selling stock -- what it means for you.
Nov 14, 2012 by Brenton Flynn1 Trend Cutting Into Intuitive Surgical's GrowthScreening changes weigh on Intuitive's growth
Nov 14, 2012 by Brenton FlynnA New Market for Intuitive Surgical?It recently received clearance for a new instrument for surgical stapling.
Nov 14, 2012 by Brenton FlynnHot off the Press: MAKO Grabs Some DineroMAKO taps the market with a secondary offering.
Nov 13, 2012 by Brenton Flynn and Max MacalusoGilead Hits the Jackpot With HCV DrugPerfection is unattainable, right?
Nov 13, 2012 by Brenton Flynn and Max MacalusoConference Commentary Boosts SareptaLondon conference commentary supports a strong 62-week release.
Nov 13, 2012 by Brenton Flynn and Max MacalusoClovis Gets Creamed After Cancer Drug FailureAnother one bites the dust.
